In Vivo Determination of Knee Kinematics for Subjects Having a Zimmer-Biomet Persona PCR or PS TKA
Conditions: Arthroplasty, Replacement, Knee, Osteoarthritis, Knee
Sponsor: The University of Tennessee, Knoxville

,Q9LYR'HWHUPLQDWLRQRI.QHH.LQHPDWLFVIRU6XEMHFWV+DYLQJD=LPPHU%LRPHW3HUVRQD
3&5RU367.$

PI: Richard D Komistek, PhD 
University of Tennessee 
1506 Middle Drive 
310 Perkins Hall 
Knoxville, TN 37996 
Phone: (865) 974-2093 
Fax: (865) 946-1787 
Email: rkomiste@utk.edu
Co-I : Jean Noël Argenson, MD, PhD 
The Institute for Locomotion 
Aix-Marseille University, Hopital Sainte-Marguerite 
270 Boulevard Sainte-Marguerite, 13009, Marseille, France
Phone: +33 491 745 011 
Email: Jean-noel.ARGENSON@ap-hm.fr  
Sub-I : Matthieu Ollivier, MD, PhD 
The Institute for Locomotion 
Aix-Marseille University, Hopital Sainte-Marguerite 
270 Boulevard Sainte-Marguerite, 13009, Marseille, France
Phone: +33 491 745 011 
Email: ollivier.mt@gmail.com  
Sub-I : Paul Bizzozero, MD 
The Institute for Locomotion 
Aix-Marseille University, Hopital Sainte-Marguerite 
270 Boulevard Sainte-Marguerite, 13009, Marseille, France
Phone: +33 491 745 011 
Email: paulbizzozero@gmail.com  
Sub-I: Adrija Sharma, PhD 
University of Tennessee 
1506 Middle Drive 
310 Perkins Hall 
Knoxville, TN 37996 
Phone: (865) 974-7684 
Fax: (865) 946-1787 
Email: asharma1@utk.edu

IRB Approved at the 
Protocol Level 
Jan 03, 2019
20183083
IRB Approved at the 
Protocol Level 
Jan 03, 2019

2 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
,QWURGXFWLRQ
A better understanding of knee joint kinematics is important to explain the premature 
polyethylene wear failures, patient dissatisfaction with function and to help design a prosthesis 
that most closely approximates the normal knee.  Previously, most experimental studies of knee 
kinematics have involved cadaveric, in vitro analyses, or have not tested the knee in a weight-
bearing mode.  Others have used exoskeletal linkages and skin markers that permit error due to 
undesired motions between markers and the underlying bone.  More recently, fluoroscopy has 
been used to assess in vivo kinematics for subjects having a TKA. These in vivo studies have 
defined the following abnormal kinematic patterns that exist with total knee arthroplasty (TKA), 
in comparison to the normal knee: 
1. 
Most subjects having a posterior cruciate retaining PCR TKA and some having a 
posterior stabilized (PS) TKA experience a paradoxical translational of the femoral component 
relative to the tibial component 
2. 
All TKA types experienced a significant percentage of subjects having reverse axial 
rotation, where the femoral component internally rotates with increasing knee flexion, opposite 
of the normal knee. 
3. 
All TKA types demonstrate the occurrence of condylar lift-off, where one condyle raises 
off the tibial plateau.   
New TKA continue to be designed and marketed to the patient and surgeon, but are these designs 
significantly different than those previously offered?  What is the rational for those design 
changes and do they truly offer an advantage?  More recently, Zimmer-Biomet brought a new 
knee implant to the orthopaedic market, called the Persona TKA.  This family of TKA includes 
both a posterior stabilized and posterior cruciate retaining design for the surgeon to choose.
More recently, surgeons have implanted both the PCR and PS Persona TKA into patients, but as 
of today Zimmer does not have in vivo data validating their design or have compared the 
kinematic results with those patients previously evaluated having either a NexGen PCR or PS 
TKA.  Therefore, the objective for this study is to analyze the in vivo kinematics for patients 
implanted by two surgeons having either a Zimmer-Biomet Persona PCR or PS TKA. 

+\SRWKHVLV
1. 
It is hypothesized that subjects having a PS TKA will experience greater posterior 
femoral rollback, axial rotation and weight-bearing flexion than subjects having a PCR TKA. 
2. 
It is hypothesized that subjects having a Persona TKA will experience better kinematic 
patterns than subjects previously analyzed having a NexGen TKA. 

6WXG\GHVLJQIn vivo knee kinematics will be assessed for 25 subjects that have been implanted 
with a Zimmer-Biomet Persona fixed bearing posterior stabilizing (PS) total knee arthroplasty 
(TKA) by Dr. Jean Noel Argenson of the Institute for Locomotion, Aix-Marseille University, 
Hopital Sainte-Marguerite. The other 25 subjects with the Zimmer-Biomet Persona fixed bearing 
poster cruciate retaining (PCR) TKA will be provided by another surgeon at a separate site, 
which has yet to be determined. Dr. Ollivier and Dr. Bizzozero both of the Institute for 
Locomotion, Aix-Marseille University, Hopital Sainte-Marguerite will serve as Sub-
Investigators. Dr. Adrija Sharma of the University of Tennessee will also serve as a Sub-
Investigator. Enrollment will be increased to 28 subjects per implant type to ensure that 
researchers acquire the necessary 25 usable datasets for analysis for each implant type and also 

3 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
to account for any subjects that may drop out of the study. All TKAs should be judged clinically 
successful (KSS > 75).  Each subject should have a well-functioning prosthesis, be at least six 
months post-operative, and should have good-to-excellent post-operative passive flexion.
Deciding which subjects received which kind of implant was up to the discretion of the study 
surgeon, according to his professional opinion. The determination as to which type of implant 
subjects received is outside the scope of this particular study. Subjects will already have the knee 
implants and must be at least six months post-operative.  
,QFOXVLRQDQGH[FOXVLRQFULWHULD
We will use the following inclusion criteria to recruit participants for this study:
1. Subjects will have a Zimmer Persona fixed bearing PS TKA. 
2. Subjects must be at least six months post-operative. 
3. Subjects will have KSS greater than 75. 
4. Participants must be able to perform the required activities - stepping up and a deep knee 
bend.
5. Subjects must be willing to sign the Informed Consent (IC) / HIPAA form to participate 
in the study.
6. Bilateral subjects may be included in the subject population. 
Exclusion criteria: 
1.
Pregnant, potentially pregnant or lactating females. To satisfy radiation protocol, each 
female subject will be asked if she is pregnant, or possibly could be pregnant. A 
pregnant person will not be allowed to participate in the study. To ensure this, a 
pregnancy test will be administered to any female participants of child bearing age 
who have not had a hysterectomy.  
2.
Subjects without the required type of knee implant. 
3.
Subjects who are unable to perform stepping up and deep knee bend. 
4.
Subjects who are unwilling to sign Informed Consent/HIPAA documents. 
5.
Subjects who do not speak English and/or French. 
6WXG\ORFDWLRQV
Subject Recruitment will take place at The Institute for Locomotion 
Aix-Marseille University, Hopital Sainte-Marguerite 
270 Boulevard Sainte-Marguerite, 13009, Marseille, France
Phone: +33 491 745 011
Fluoroscopic and range of motion exams will be performed on 28 PS TKA subjects at:  
The Institute for Locomotion 
Aix-Marseille University, Hopital Sainte-Marguerite 
270 Boulevard Sainte-Marguerite, 13009, Marseille, France
Phone: +33 491 745 011 
Analysis will take place at the University of Tennessee’s Center for Musculoskeletal Research 
laboratories:
Science and Engineering Research Facility  

4 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
1414 Circle Dr. 
Knoxville, TN 37996 
CMR administrative offices: 
310 Perkins Hall
1506 Middle Dr.
Knoxville, TN 37996 
5HFUXLWPHQW
Dr. Argenson will recommend eligible subjects for recruitment that have been implanted with the 
Zimmer Persona PS TKA whose post-operative conditions permit them to capably perform the 
study activities. Drs. Ollivier and Bizzezero will be responsible for reviewing those subjects’ 
medical records to determine if they meet the remaining eligibility required for the study 
according to the study-specific criteria. A Request for Partial Waiver of HIPAA Authorization 
for the purposes of recruitment will be submitted.  
During review of medical files, Drs. Ollivier and Bizzezero will ensure that each potential 
subject meets all eligibility requirements prior to being contacted about participation in the study. 
If patients meet all eligibility criteria, then Drs. Ollivier or Bizzozerowill contact the patients to 
explain the study, using the included script, and inquire as to whether or not they are interested in 
participating; If a subject is agreeable to participate, Drs. Ollivier or Bizzozero will schedule a 
time for the patient to visitthe Institute for Locomotion on the day of data collection. On this 
scheduled day, UT researchers will travel to the Institute for Locomotionto collect the kinematic 
data of participant implanted knees at least six months post-operatively under fluoroscopic 
surveillance using a C-arm fluoroscopic unit while subjects perform the following activities: 
stepping up and a deep knee bend. The fluoroscopic images will be stored on videotape and/or 
external hard drive for subsequent analysis.
'DWD&ROOHFWLRQ
On the day the fluoroscopic procedures will take place, researchers selected by Dr. Richard 
Komistek, student research assistants (Garett Dessinger, Jarrod Nachtrab, Manh Ta, Milad 
Khasian) with the Center for Musculoskeletal Research (CMR) will travel tothe Institute for 
Locomotion to collect the data. A study Investigator will be present for the fluoroscopy 
procedures. Drs. Ollivier or Bizzozero will consent the participants. They will meet with each 
potential participant individually to make sure s/he has been properly informed of the procedures 
and to help with any of the IC/HIPAA form. Subjects will be informed that they do not have to 
participate and are free to leave if they wish and will answer any questions subjects may have 
about the study. Participation is entirely voluntary. 
After consent has been obtained and eligibility has been confirmed, a study physician will 
administer the New Knee Society Score survey to all participants.  
In addition to fluoroscopy video, subjects will be videotaped from the shoulders down (to 
maintain subject anonymity) while performing the activities (live feed perspective).  During the 
fluoroscopy procedure, the radiation technician (RT) will follow the motion of the implanted 
knee with the fluoroscopy machine; only the knee joint (from the fluoroscopy machine) will be 

5 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
recorded on the fluoroscopy footage. The practice portion of the data collection without radiation 
will not be video-recorded. The participant will be allowed to rest as necessary and be instructed 
to stop the activity at the first sign of pain. The speed level of each trial will be based on the 
comfort level of the subject. One of the researchers will be ready and in close proximity to assist 
each subject in case the participant requires help. This precaution will be practiced for all 
participants, regardless of physical wellbeing, age or prior results; no assumptions will be made 
as to any participant’s capabilities. 
Multiple trials of each activity may be conducted to ensure usable images have been acquired to 
complete the study. Radiation time will be kept as low as reasonably achievable (ALARA) and 
will not exceed two minutes. The RT will start the fluoroscope just prior to the subject beginning 
each activity trial and will stop the fluoroscope immediately after the subject completes each 
activity trial to ensure that the subject is not exposed during idol periods. Fluoroscopy on-time 
will be recorded on each subject’s IC. 
When both the subject and study team are ready, the following activities will be performed: 
1. Step up
a) The subject will begin standing at rest with his/her knee in question slightly 
forward in front of a small set of portable stairs. 
b) The subject will then begin to ascend the stair case beginning with her/his lead 
foot, making sure that with each step, the foot is landing one step above the 
other.
 
2.  Deep knee bend 
a) The subject will begin standing in a starting position in which the knee is fully 
extended. When ready the subject will flex the knee through its full weight 
bearing range of motion. Once maximum weight bearing flexion is achieved the 
activity is complete, and the subject can rise to a comfortable resting position. 
The fluoroscopic footage for these activities will be stored on digital video files on a secure 
computer workstation, and participant information will be removed and replaced with identifiers 
by researchers selected by Dr. Komistek to lead the study, which may include any researchers 
that attend data collection. All researchers with access to identifiable subject data will sign 
statements of confidentiality. This study data will then be uploaded onto a secure server that 
University of Tennessee researchers will use to conduct the kinematic analysis using a 3D-to-2D 
image registration technique the allows researchers to determine the 3D kinematics of the tibio-
femoral joint for each of the frames in question. Once each of the frames has been analyzed for a 
single participant, kinematic curves can be produced to describe the motions of the joint. It is not 
feasible for a participant to be identified merely by the components within their individual 
implants. 
3ULYDWH+HDOWK,QIRUPDWLRQ0HGLFDO5HFRUG'DWD
The surgeon and his staff will provide subjects’ clinical information from their medical records – 
PHI – to Dr. Komistek and his researchers to aid in the interpretation of the results and correlate 
clinical outcomes versus kinematic results, although only researchers present during data 
collection or those appointed by Dr. Komistek to lead the study will have access to PHI; they 
will sign confidentiality statements. This information can be used to rule out any unique 

6 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
kinematic patterns. This information will only be used by the UT researchers and will not be 
provided to any other source.
The clinical/demographic information acquired from the medical records with participant 
authorization obtained as required by HIPAA will include: 
• the range-of-motion (at least 6 months post-operative),  
• DOB, body weight, Body Mass Index (BMI), 
• date of surgery, 
• Subjects post-operative KSS (must be >75), 
• previous medical assessments that are not a part of this particular research study, that 
may alter the kinematic results, such as previous knee x-rays, 
• post-operative time and any other conditions that may alter the kinematic results, such as 
back problems, ankle fusion, or contra-lateral knee problems.  
The surgeon’s office will also relate the implant component information and surgical technique 
details:
• Size of: femur, tibial plate, articular surface thickness [mm], patella 
• Product/Reference # of: femur, tibial plate, polyethylene (PE) insert, patella 
• Lot # of: femur, tibial plate, PE insert, patella  
• Surgical operation notes 
• Use (if any) and details of intraoperative surgical technologies, such as robotic 
assistance, subject-specific cutting guides, surgical navigation, etc. 
The subject data – fluoroscopy frames, video footage and data from medical files– will be 
uploaded and stored on CMR’s secure server for use in this and future studies (if participant 
permission is obtained via IC) by the researcher(s) who attend data collection or appointed by 
Dr. Komistek. Once data has been uploaded, the database automatically removes subject 
identifiers and assigns an ID for each subject. Only these files of de-identified data (no dates of 
birth or surgery) are now available for researchers to review and analyze. Only Dr. Adrija 
Sharma (Sub-I) has access to the identifiable data that was originally uploaded by the GRA, as it 
remains in a password-protected portion of the secure server. Only Dr. Sharma can grant access 
to this identifiable password-protected portion of the database by changing a user's level of 
authentication with different privilege levels. Researchers would like to retain this study data in 
our secure database so as to continue to add relevant, current data to our digital collection to help 
us work with manufacturers in the future to create better implants that last longer and will not 
require revision surgery. Participants will be asked if their study data may remain a part of the 
CMR data collection for use in future studies in the IC. Likewise, should a subject choose to 
withdraw from the study, s/he will have the option as to whether or not data collected from them 
at the point of withdrawal may be used for data analysis or if their information should be 
destroyed from CMR records; subjects choosing to withdraw will be asked to complete a 
Revocation of Consent wherein they may indicate their preference regarding the data collected 
from them. 
On the day of data collection, the list of subject names will be given to UT researchers and the 
researchers will use this to generate subject-specific identifiers. A table will be generated for this 
study, indicating the participant’s name and generated ID number; this table with subject names 

7 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
and corresponding ID numbers will be provided to the surgeons’ staff, so the staff will be aware 
of which identifier is linked with each subject. Then, study staff will upload the PHI from 
medical files into an excel spreadsheet created by the UT researchers present during data 
collection or those appointed by Dr. Komistek (who will sign statements of confidentiality) that 
will only have the generated ID numbers. This spreadsheet will be securely transferred to UT 
researchers via UT’s secure email known as the Vault. See ‘Computer Database’ section under 
Participant Confidentiality for additional details regarding the actual acquisition of PHI data 
from the surgeon’s office. 


63(&,),&5,6.6$1'3527(&7,210($685(6
 )OXRURVFRSLF3URFHGXUHV
As with every clinical study, there may be some risks.  However, doses of radiation exposure 
received will be much lower than those known to produce detectable health effects.  Previously 
reported literature shows that fluoroscopy-based procedure (angiography) on the lower limb 
result in a typical effective dose of 0.83 mSv per min (0.083 rem per min) (Verdun1).  Mettler, et 
al. have reported that the typical effective dose for a conventional knee procedure is 0.005 mSv 
(0.0005 rem)2.  According to either estimate, the additional risk of a fluoroscopic procedure 
involving the knee ranges between "Negligible" to "Low" for a 2 minute exam (Verdun).  A 
previous fluoroscopy TKA study conducted at another hospital with a 2 minute on-time limit 
shows that the average effective dose was 0.14 mSv (0.0014 rem) with a maximum dose of 0.27 
mSv (0.027 rem).  The additional risk for all subjects in this previous study would be considered 
"Negligible."  To account for subject variability and differences in imagining techniques, all 
subjects enrolled in this study will receive fewer than 2 rem.  2 rem is considered "Low" risk.  It 
is unlikely that anyone in this study will approach the 2 rem limit. Since the fluoroscopy data 
will be collected in one session, there will only be one day in which the participants will be 
exposed to this amount of radiation. 
In conclusion, a participant who will be fluoroscoped for less than two minutes will be exposed 
to a PD[LPXP amount of only 2.0 rems of radiation. This means that the maximum total 
exposure rate will be less than 2 rems per subject for the entire experiment (Attachments 3 and 
4).  The participant's knee joint will be fluoroscoped using negligible to low risk levels of 
radiation according to published literature (Attachments 2 and 3).  
The participant has the right to stop the procedure at any time; researchers or the RT can end the 
procedures at any time if they feel the participant is at risk, but the participant can choose to 
remain in the study if s/he feels that there is no risk to her/his surgical procedure or recuperation.
                                                          
1 Verdun FR, Bochud F, Gundinchet F, Aroua A, Schnyder P, Meuli R. Quality Initiatives Radiation Risk: What 
You Should Know to Tell Your Patient 1. 5DGLRJUDSKLFV 2008 Nov 28(7):1807-16. 
2 Mettler, et al. “Effective Doses in Radiology and Diagnostic Nuclear Medicine.” 5DGLRORJ\ 248.1 (2008): 254-263. 
http://radiology.rsna.org/content/248/1/254.full.pdf+html

8 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
Researchers will be at the hospital during the fluoroscopic exams, serving as consultants to the 
hospital RT. They will not operate the fluoroscopy unit, but will be available to the RT and the 
hospital staff if questions arise. Researchers will be on hand to assist the participant at any time 
during the procedure. The participant has the right to stop the procedure at any time; researchers 
or the RT can end the procedures at any time if they feel the participant is at risk, but the 
participant can choose to remain in the study if s/he feels that there is no risk to her/his surgical 
procedure or recuperation. If researchers and the investigator during data collection concur that a 
subject is at risk and the subject persists in participating, the researchers will ask the subject to 
discontinue the activities and not to participate in the study. 
We are estimating a total maximum time of 45 minutes to permit the subject time to complete the 
IC/HIPAA form, ask any questions s/he may have, practice the activities or repeat any activities 
that could not be completed, and collect all necessary fluoroscopy data from each subject.  
2. 3DUWLFLSDQW&RQILGHQWLDOLW\
The investigators will ensure subject confidentiality to the extent that is permissible by law is 
maintained throughout the study and after. Researchers not notated as Investigators of this study 
that have access to PHI will sign pledges of confidentiality. Complete confidentiality cannot be 
guaranteed.
&RPSXWHU'DWDEDVH
As noted, on the day of data collection, the list of subject names will be given to UT researchers 
and researchers will use this to generate subject-specific identifiers; the surgeons’ study staff will 
be provided with this list of subject names and corresponding generated identifiers that they will 
use to upload into an excel spreadsheet created by UT researchers. The excel spreadsheet with 
and transmit the document back to UT researchers via UT’s secure email transmission known as 
the Vault, https://vault.utk.edu/.
After the study data has been entered into the spreadsheet by the surgeon’s office, researchers 
present during data collection or appointed by Dr. Komistek will upload the subject data, 
including PHI, fluoroscopy, and video footage, into the CMR digital data collection. 
Consequently, student researchers in CMR who assist in data analysis cannot access subject-
specific information. All participant queries (lookups) generate the participant identification 
number (the ID generated by UT researchers) and no subject identifiers.  No identifiable images 
exist in the database. This study data will be kept indefinitely on the secure CMR database for 
possible future research (with the permission of each participant – requested in the IC). In the 
case of participant withdrawal from the study, the Revocation of Consent that the participant will 
be asked to complete requests that the participant indicate whether or not data collected prior to 
withdrawal may be used for data analysis purposes, or if it should be removed from the CMR 
data collection completely and destroyed. 
+DUG&RS\
In compliance with HIPAA regulations, all participants will have their identities withheld from 
all public files. Individuals not indicated as Investigators below will have access to participant 
information and they will sign pledges of confidentiality. The personnel in the following list will 
have access to participant PHI: 

9 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
/LVWRI3HUVRQV,QYROYHGLQ5HVHDUFK
• Richard Komistek, PhD, PI, UT Professor, Biomedical Engineering 
• Jean Noël Argenson, MD, PhD, Co-I, The Institute for Locomotion, Aix-Marseille 
University, Hospital Sainte-Marguerite, orthopaedic surgeon 
• Matthieu Ollivier, MD, PhD, Sub-I, The Institute for Locomotion, Aix-Marseille 
University, Hospital Sainte-Marguerite, orthopaedic fellow 
• Paul Bizzozero, MD, Sub-I, The Institute for Locomotion, Aix-Marseille University, 
Hospital Sainte-Marguerite, orthopaedic fellow 
• Dr. Adrija Sharma, PhD, Sub-I, UT Research Assistant Professor, Biomedical 
Engineering
• Radiation technician(s) will operate the fluoroscopy machine 
• A study investigator will be present during the fluoroscopy procedure.
• Rebecca Robertson, Research Coordinator, UT staff. 
• Researchers present during data collection at the University of Tennessee and/or the lead 
researchers appointed by Dr. Komistek.  
• Graduate students: 
 Garett Dessinger 
 Jarrod Nachtrab 
 Milad Khasian 
 Manh Ta 
• * Undergraduate student researchers employed by CMR will be involved in 
analyzing the data after it has been collected and transferred to CMR’s digital 
data collection. Since subject information will be removed and replaced with the 
assigned identifiers before the data is transferred to the database, it will not be 
possible for these undergraduate students to be able to identify subjects. They 
will only have access to the study data that has been uploaded onto the secure 
CMR digital collection. These undergraduate student researchers will not have 
contact with subjects, unless they are part of the data collection team. 
• Institutional Review Board/Ethics Committee  
• The University of Tennessee will waive oversight to WIRB. Waiver of Oversight 
is forthcoming. 
• The Institute of Locomotion will waive oversight of study to WIRB. Waiver of 
Oversight is forthcoming. 
&OLQLFDO2EVHUYDWLRQV
There are no clinical observations made during this data collection or from the images obtained 
through data collection. There will be no radiology report generated for this procedure conducted 
as a result of this study. Therefore, no RT will review such a report for the procedures, which 
would be the only way such a “significant problem” would be determined. If researchers see 
anything in the imaging that is extremely out of the ordinary (HJfloating body, severe 
dislocation, potential tumors [spots of incredibly dense tissue on bones and skin]), they will bring 
this to the attention of Drs. Argenson, Ollivier, or Bizzozero. It is not anticipated that the 
imaging collected during this study would potentially provide benefit to specific subjects by 
influencing the physician’s treatment plan. 

10 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
%(1(),76
The potential benefits from this study include, but are not limited to: 
• Better understanding of the joints analyzed with the same technique in the past. 
• Future implant design improvements based on the kinematic findings. 
• New and advanced surgical techniques for TKA based on the results.
• Information related to the data gathered may be provided to the surgeon by the 
researchers if something out of the ordinary is seen during the imaging. However, 
researchers are not radiologists and cannot interpret anything they may see. If there is 
something within the imaging that is obviously wrong as mentioned above, then this 
could result in potential modification of a subject’s treatment plan if images collected as a 
result of this study reveal any kind of “significant problem.” 
0(7+2'6722%7$,1,1)250('&216(17)5203$57,&,3$176
Informed consent will be obtained prior to any procedures being conducted. Subjects who are 
agreeable to participate will be scheduled to visit on the day that UT researchers will travel to the 
Institute for Locomotion for data collection. Participating physicians from the Institute will be 
responsible for consenting the participants, giving them ample time to review and complete the 
forms and assist the participants with review of the documentation, if the participants are unable 
to read the form on their own. Only upon signed consent will the subject be allowed to 
participate in the study. If the subject chooses to be removed from the study after participating, 
his/her video footage and any other demographical data that was collected will be managed 
according to the subject’s response on the Revocation of Consent form. A copy of his/her 
Revocation of Consent will be attached to his/her IC and placed in a separate, secure file for IRB 
review. These consent forms will be stored at UT, Knoxville and will be accessible by only the 
aforementioned personnel.  
Dr. Argenson will not be present during the consenting process to avoid possible subject 
coercion to participate. Subjects may contact the surgeon’s office with any questions they may 
have.
From previous studies, we have determined that it takes approximately 15 minutes to consent a 
subject and answer any questions that s/he may have. We have also estimated approximately 30 
minutes for researchers to guide the subject through the steps of the procedure, allow the subject 
to practice the activities and then to actually perform the activities under fluoroscopic 
surveillance; actual radiation exposure will be up to, but not more than two minutes. We have 
estimated a total time of approximately 45 minutes for each subject to be consented, complete 
the fluoroscopy procedure.





11 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 

$77$&+0(17
Verdun FR, Bochud F, Gundinchet F, Aroua A, Schnyder P, Meuli R. Quality Initiatives 
Radiation Risk: What You Should Know to Tell Your Patient 1. 5DGLRJUDSKLFV 2008 Nov 
28(7):1807-16.






12 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 


































13 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
$77$&+0(17
Mettler, et al. “Effective Doses in Radiology and Diagnostic Nuclear Medicine.” 5DGLRORJ\
248.1 (2008): 254-263. http://radiology.rsna.org/content/248/1/254.full.pdf+html




14 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
$77$&+0(17

15 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 

16 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 

17 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 

18 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
$77$&+0(17




19 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 



20 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 

21 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 

22 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 




23 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 






24 Argenson, Ollivier, Bizzozero -- Zimmer-Biomet Persona PS vs PCR TKA protocol V1.3 
11/20/2018 
